amisulpride / Generic mfg. - LARVOL DELTA

Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders (ECNP 2025) - "The gene expression profiles suggest that previous exposure to antipsychotics primes some individuals for an inflammation-like response when changing to a different antipsychotic drug. No conflict of interest"

Clinical • CNS Disorders • Psychiatry • Schizophrenia • CTSG • ELANE • MPO • SELENBP1 • SLPI • SPTB • TMC2

Psychodermatology in early psychosis: optimising the mind-skin link (ECNP 2025) - "Participants were aged 18–40, met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder, had a duration of psychosis <24 months, minimal or no prior antipsychotic exposure (≤2 weeks at baseline), and all received open-label amisulpride treatment for 4 weeks [5]... Our findings suggest that DS may represent a marker of illness severity and poor short-term outcomes in the early stages of psychosis, potentially identifying a subgroup of patients with a poorer clinical prognosis who may benefit from early tailored interventions. Further research is warranted to explore the potential role of DS as early clinical predictors in psychosis."

CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia • Schizophreniform Disorder

Comparative evaluation of the impact of clozapine and other antipsychotics on insight in schizophrenia (ECNP 2025) - "Among them, 20 patients were prescribed Clozapine, and the remaining 20 patients were prescribed other antipsychotic medications (such as Risperidone, Olanzapine, or Amisulpride). However, the higher risk of certain side effects associated with clozapine should also be taken into consideration when making treatment decisions. Further research and larger-scale studies are necessary to confirm these findings and explore the long-term effects and safety profiles of these medications."

CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Psychosis-mimicking Niemann-Pick Type C case with neuropsychiatric signs underscores importance of early diagnosis in atypical presentations (ECNP 2025) - "Initially diagnosed with generalized anxiety disorder, she was treated with sertraline and risperidone, showing partial improvement. However, psychotic symptoms persisted, leading to an increase in risperidone dosage and the addition of quetiapine, with minimal effect.The patient later developed urinary incontinence, which was attributed to risperidone after ruling out organic causes. Risperidone was replaced with amisulpride, resulting in improvement of both the psychotic symptoms and the incontinence...NPC should be considered in the differential diagnosis of psychosis with an atypical course and neurological features. Genetic testing should be considered in selected cases to facilitate early diagnosis and appropriate management."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry • Schizophrenia • NPC1 • NPC2

Atypical neuroleptic malignant syndrome due to antipsychotic discontinuation in a 38-year-old patient with schizophrenia and ankylosing spondylitis following ileus (ECNP 2025) - "Diagnosed with ileus, his antipsychotic medications — clozapine (300 mg/day), risperidone (2 mg/day), and quetiapine (100 mg/day)—were discontinued...Previous treatments included olanzapine, haloperidol, amisulpride, clozapine and paliperidone...Infectious disease specialists started antibiotics and rheumatology initiated adalimumab (40 mg/2 weeks)...Bromocriptine (15 mg/day), amantadine (300 mg/day) and diazepam (10 mg/day) were introduced, followed by careful titration of quetiapine to 250 mg/day... NMS is clinically characterized by hyperthermia, muscular rigidity, altered consciousness, autonomic dysfunction, elevated serum creatine phosphokinase levels and leukocytosis. Risk factors include high-potency antipsychotic use, young age, male sex, movement disorders, and comorbid neurological or medical conditions. Rapid dose escalation, abrupt discontinuation, anticholinergic withdrawal, dehydration, and a previous history of NMS further increase the risk."

Clinical • CNS Disorders • Mental Retardation • Movement Disorders • Psychiatry • Schizophrenia • Sleep Disorder

Neural and behavioral effects of dopaminergic modulation in delay discounting: a pharmacological functional magnetic resonance imaging study in healthy participants (ECNP 2025) - "Specifically, we investigate how acute administration of the D2/D3 antagonist amisulpride and the dopamine precursor L-dopa affects choice behavior and associated brain activity, compared to placebo...Clinical relevance: Delay discounting has been shown to be a transdiagnostic marker of impulsivity, with altered discounting rates observed in a range of psychiatric conditions, including substance use disorders, ADHD, eating disorders and mood disorders [4,5]. Understanding how dopamine shapes temporal reward preferences in healthy individuals can help identify targets for interventions aimed at reducing impulsive decision-making and its associated burden in clinical populations."

Clinical • MRI • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Psychiatry

Pharmacological strategies targeting negative symptoms in schizophrenia (ECNP 2025) - "In a 14-week RCT versus risperidone (n = 460), it achieved a 2.6 point greater reduction on the PANSS Negative subscale (p<0.001) and improved social functioning [4]. Low-dose amisulpride and lurasidone have shown moderate benefits, particularly when negative symptoms are secondary to depression or extrapyramidal effects...Cholinergic modulation with xanomeline–trospium recently showed significant reductions in both positive and negative symptoms in a phase II trial (n = 182), suggesting a novel non-dopaminergic approach. Antidepressant augmentation (primarily SSRIs and mirtazapine) produced modest additional benefits, though heterogeneity across studies tempers confidence [5]... Emerging pharmacotherapies targeting dopamine D3 receptors, serotonergic modulation and glutamatergic pathways offer promising avenues for alleviating negative symptoms in schizophrenia. Cariprazine and roluperidone have demonstrated the most robust RCT evidence, memantine is a viable adjunct..."

CNS Disorders • Depression • Psychiatry • Schizophrenia

Management of breakthrough psychosis on antipsychotic maintenance medication in a patient treated with long-acting injectable antipsychotic (ECNP 2025) - "The patient was treated with several oral antipsychotics, including amisulpride, olanzapine and aripiprazole. He began treatment with aripiprazole once-monthly 400 mg (AOM 400) after the last discharge in 2019...Conclusions The BAMM phenomenon has also been reported in relation to other long-acting injectable antipsychotics, such as Risperidone or Paliperidone, however, the available data is limited compared to those for aripiprazole [3,4]. This phenomenon reveals that, in some treatment-adherent patients, psychotic symptoms may resurface, especially in stressful situations. Close monitoring and identification of potential causal factors are key to optimizing long-term treatment outcomes."

Clinical • CNS Disorders • Mood Disorders • Psychiatry • Psychomotor Agitation • Schizophrenia • Substance Abuse

Prescribing patterns of antipsychotic monotherapy and polypharmacy in patients with psychotic disorders (ECNP 2025) - "Among monotherapy patients, olanzapine was most frequently prescribed (33.3%), followed by risperidone and haloperidol (both 18.2%), quetiapine (15.2%), aripiprazole (9.1%), and clozapine (6.1%)...Less frequently prescribed in polytherapy were aripiprazole (10.4%), risperidone (7.3%), levomepromazine and zuclopenthixol (both 6.3%), fluphenazine (4.2%), and amisulpride and sulpiride (both 1.0%)... Despite guideline recommendations that advocate for antipsychotic monotherapy whenever possible [1,3], this study found that polypharmacy remains prevalent in clinical practice. Olanzapine emerged as the most common choice in monotherapy regimens, while haloperidol and promazine were more frequently used in polytherapy. Clozapine, despite its well-established role in treatment-resistant schizophrenia, was more commonly prescribed as part of combination therapy (16.7%) than as monotherapy (6.1%)."

Clinical • Monotherapy • CNS Disorders • Psychiatry • Schizophrenia

Psychotic dimensions of mesial temporal sclerosis: diagnostic challenges beyond epileptic seizures (ECNP 2025) - "Treatment with amisulpride 200 mg/day and mirtazapine 7.5 mg/day was initiated...Aripiprazole was introduced, resulting in modest improvement in agitation and aggression, mild improvement in psychotic symptoms...She had been receiving levetiracetam, zonisamide, and valproic acid. Tremor led to valproate discontinuation and lacosamide initiation which in turn led to temporary increase in seizure frequency... This case highlights the need for a multidisciplinary approach in evaluating psychosis in epilepsy. History-taking, EEG, and neuroimaging are essential for distinguishing epilepsy-related psychosis from primary psychiatric conditions. Although relatively uncommon, psychotic symptoms in drug-resistant TLE should be investigated in terms of interictal psychosis, especially when supported by clinical and neurophysiological evidence."

CNS Disorders • Epilepsy • Insomnia • Mental Retardation • Movement Disorders • Psychiatry • Schizophrenia • Sleep Disorder

Prolactin response to six-month paliperidone palmitate. Preliminary results (ECNP 2025) - "One such strategy is to add low-dose aripiprazole to the selected antipsychotic regimen. Newer antipsychotics, particularly risperidone, amisulpride, and paliperidone, and older antipsychotics, particularly chlorpromazine, haloperidol, and sulpiride, increase prolactin levels with significant side effects...In other words, the mean difference in PRL values between patients treated with monthly paliperidone (PP1M) and those same patients treated with six-month paliperidone (PP6M) is 35.57 μg/L. This difference is due to the change in treatment and not to chance. Treatment with six-month paliperidone (PP6M) significantly improves blood prolactin levels, effectively reducing them by half."

CNS Disorders • Mental Retardation • Psychiatry • PRL

Late-onset psychosis in an elderly patient: a diagnostic challenge between psychosis and dementia (ECNP 2025) - "Treatment/Management Multiple pharmacologic strategies were trialed: • Antidepressants: Sertraline, Mirtazapine.• Antipsychotics: Olanzapine, Risperidone, Quetiapine, Flupentixol, Amisulpride.• Anxiolytics/Sedatives: Lorazepam, Clonazepam, Zopiclone.• Procyclidine was used for EPSEs.• Supportive care included 1:1 nursing, nutrition support, and routine antibiotics for incidental infections.Clinical Course/Outcome Despite treatment, the patient remained significantly cognitively impaired and functionally dependent. The patient's abrupt decline and poor response to antipsychotics , combined with cognitive testing, led to a provisional diagnosis of frontotemporal dementia. ."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • Psychiatry

Comparing the effects of different antipsychotics on cortical thickness (ECNP 2025) - " We compared the effects of clozapine, olanzapine, flupentixol, amisulpride and risperidone on cortical thickness. Antipsychotic medications have variable effects on cortical thickness. The use of clozapine, olanzapine or flupentixol appears to lead to cortical thinning that is somewhat similar to the pattern observed in the ENIGMA study. Low cerebral blood volume, and in the case of clozapine and olanzapine, high dopamine D2 levels may render brain regions susceptible to cortical thinning."

CNS Disorders • DRD2

A case of treatment-resistant depression unresponsive to multiple antidepressants, antipsychotics, mood stabilizers, and electroconvulsive therapy is presented (ECNP 2025) - "He was started on fluoxetine 40 mg/day at an external center in early 2023...Due to lack of clinical improvement, olanzapine 2.5 mg/day and venlafaxine 75 mg/day were initiated, with the latter increased to 150 mg/day. His suicidal ideation and restlessness worsened, leading to further emergency admissions and multiple medication adjustments.The patient was subsequently treated with a series of psychotropic medications, including escitalopram (up to 20 mg/day), clonazepam, lorazepam, amisulpride, and clomipramine, in various combinations...He was hospitalized multiple times and underwent six sessions of ECT, without significant improvement.Later, his regimen was modified to include quetiapine (100 mg/day IR and up to 200 mg/day XR), trifluoperazine, and alprazolam...Mood stabilizers, including valproic acid 750 mg/day and lamotrigine up to 100 mg/day, were introduced, along with aripiprazole and continued quetiapine...In this patient, persistent suicidality, poor..."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychiatry • Suicidal Ideation

Management of severe irritability and inappropriate sexual behavior in an adolescent with autism spectrum disorder: Clinical response to amisulpride (ECNP 2025) - "Risperidone and aripiprazole are FDA-approved medications for ASD-related irritability, but adverse effects (e.g., weight gain, sedation) may limit their use [3].Amisulpride, a D2/D3 dopamine antagonist, is rarely used in ASD but has a favorable side effect profile and theoretical benefits in controlling behavioral disinhibition...These behaviors persisted despite structured behavioral therapies.At an external center, he was prescribed risperidone 0.5 mg/day and methylphenidate 20 mg/day, followed by the addition of sertraline 50 mg/day...Cranial MRI and EEG were also normal.Initial treatment with quetiapine 25–75 mg/day was ineffective and stopped. After the patient experienced jaw stiffness following an intramuscular injection, biperiden 6 mg/day was added...The goal should always be to support self-regulation, not suppress sexuality. This case supports the cautious use of amisulpride in refractory cases, but controlled studies are needed to validate its role in ASD.."

Clinical • CNS Disorders • Mental Retardation

Response probability to single intravenous racemic ketamine with psychopharmacological combinations: a pooled post-hoc study (ECNP 2025) - "The combination of ketamine with antidepressants that block 5-HT2A receptors (such as mirtazapine, mianserine, trazodone, and agomelatine; n = 41) significantly increased the response rate to 58.5%, compared to 28.9% in those who did not receive these combinations. In contrast, combining ketamine with serotonin reuptake inhibitors (escitalopram, fluoxetine, paroxetine, sertraline, vortioxetine; n = 34) or with antipsychotics characterized by higher D2 than 5-HT2A blockade (amisulpride, aripiprazole, cariprazine; n = 10) significantly reduced the response rate to 26.5% and 0%, respectively, compared to 53.8% and 48.7% in those not receiving these combinations. Combination of ketamine with serotonin and norepinephrine reuptake inhibitors (clomipramine, venlafaxine, duloxetine, milnacipran; n = 30) or with antipsychotics (n = 40), compared to ketamine without SNRIs or without antipsychotics, did not significantly alter the probability of response (p = 0.369 and p = 0.083,..."

Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Severe cutaneous adverse reactions associated with antipsychotics: a disproportionality analysis in the Food and Drug Administration's adverse event reporting system (ECNP 2025) - "Case reports in recent years have pointed to an association between SCARs and some antipsychotics (e.g., chlorpromazine, haloperidol, aripiprazole) [2–4]...For DRESS, positive signals were found for promazine (n=20, chi-squared=371.736, PRR=21.549), droperidol (n=11, chi-squared=113.413, PRR=13.320), loxapine (n=35, chi-squared=228.181, PRR=8.623), chlorprothixene (n=3, chi-squared=5.298, PRR=4.629), chlorpromazine (n=19, chi-squared=41.881, PRR=4.123), cyamemazine (n=16, chi-squared=27.126, PRR=3.572), amisulpride (n=11, chi-squared=14.840, PRR=3.236), and haloperidol (n=49, chi-squared=31.159, PRR=2.208). Sulpiride showed positive signals for both SJS (n=4, chi-squared=10.238, PRR=5.384) and TEN (n=3, chi-squared=7.548, PRR=5.773)... The potential safety signals for certain types of SCARs were detected for several antipsychotics. While these findings are hypothesis-generating, further confirmation through large cohort and case-control studies is needed. Clinicians..."

Adverse events • CNS Disorders

Reward learning impairment from punishment-associated exploration depends on dopaminergic signaling (Neuroscience 2025) - "We found that pharmacological blockade of dopamine D2/3 receptor with amisulpride eliminated both the impairment in reward learning and the accompanying increase in exploration. These findings demonstrate that reward learning can be disrupted by punishment-driven exploration in a dopamine-dependent manner, offering a mechanistic account of how the brain resolves competing value signals and insights into dopamine-related learning disturbances in neuropsychiatric conditions."

CNS Disorders • Cognitive Disorders • Psychiatry

Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort. (PubMed, Transl Psychiatry) - "Whereas we detected multiple correlations between methylation and gene expression, few were temporally stable, such as the correlation between HOXA5 and SKAP2 expression, a gene affecting susceptibility to schizophrenia. Our findings demonstrate the strengths of prospective design in response-biomarker research and suggest that epigenetic variation associated with antipsychotic response is shaped by both the environmental and genetic factors."

Journal • CNS Disorders • Inflammation • Psychiatry • Schizophrenia • HTR2A • SKAP2

Strategic and tactic use of antipsychotic medications in schizophrenia: a perspective on current prescription practice. (PubMed, Discov Ment Health) - "Meta-analyses indicate clozapine, amisulpride, olanzapine, and risperidone as effective in acute settings, with olanzapine and haloperidol beneficial for SZ-related agitation. Empirical observations suggest higher potency APs, like olanzapine and haloperidol, are more effective in acute psychosis, with zuclopenthixol also advantageous for its sedative properties...Once the acute phase resolved, patients should be gradually switched towards a medication with fewer side effects (i.e. metabolic syndrome, extrapyramidal symptoms, hyperprolactinemia) and a potential efficacy on negative symptoms and personal functioning (i.e. cariprazine, low-dose amisulpride, lurasidone, aripiprazole, brexpiprazole), to be continued in the long term, defined as a strategic AP. This approach aligns with empirical observations and aims to refine schizophrenia care through phase-specific APs use, necessitating further studies to validate its efficacy."

Journal • Review • Anesthesia • CNS Disorders • Metabolic Disorders • Psychiatry • Psychomotor Agitation • Schizophrenia

Association of Atypical Antipsychotics With Lipid Abnormalities in Adult Patients With Schizophrenia: A Scoping Review. (PubMed, Neuropsychopharmacol Rep) - "The review shows significant associations between specific AAs and lipid abnormalities, particularly with clozapine and olanzapine. Biomarkers and genetic polymorphisms offer promising avenues for monitoring and personalized treatment. Evidence for certain AAs, such as amisulpride, paliperidone, and ziprasidone, remains sparse, highlighting the need for further targeted research. These findings support informed prescribing and the development of predictive tools to mitigate metabolic risks in the treatment of schizophrenia."

Journal • Review • CNS Disorders • Dyslipidemia • Psychiatry • Schizophrenia • APOA1 • IGFBP2

Determinants of real-world functioning in first-episode psychosis patients receiving 4 weeks of amisulpride treatment: findings from the multinational OPTiMiSE study. (PubMed, J Psychiatr Res) - "Negative symptoms, specifically amotivation and diminished expression, play a key role in real-world functioning. Amotivation impacts general and domain-specific functioning, while positive symptoms and diminished expression mainly affect aggressive behaviors area."

Journal • Real-world evidence • CNS Disorders • Depression • Psychiatry

Severity and influencing factors of hyperprolactinemia in hospitalized schizophrenia patients: a cross-sectional study. (PubMed, Front Psychiatry) - "The ordered multivariate logistic regression model showed that HPRL severity was negatively correlated with aripiprazole use, male sex, fasting glucose, aspartate aminotransferase (AST), and follicle-stimulating hormone (FSH), but positively correlated with the use of sulpiride, paliperidone, amisulpride, risperidone, blonanserin, trihexyphenidyl, and anxiolytics. HPRL is highly prevalent in schizophrenia patients, with distinct clinical profiles across severity levels. HPRL severity is associated with specific antipsychotics, anxiolytics, trihexyphenidyl, and metabolic indicators, underscoring the need for risk stratification and individualized management."

Journal • Observational data • CNS Disorders • Psychiatry • Schizophrenia • PRL

Transcriptomic and proteomic analyses of SH-SY5Y neuroblastoma cells treated with amisulpride. (PubMed, Acta Neuropsychiatr) - "Our data reveal novel insights into the role of amisulpride in modulating the differential expression of genes and proteins. These findings, which involve genes/proteins related to AP-1 transcription factor family gene regulation, cytoskeleton, histone binding activity, the intracellular trafficking of receptors and endocytosis of a variety of macromolecules, and nuclear localization signal, are particularly significant as they shed light on the molecular underpinnings of the clinical efficacy of amisulpride and the pathogenesis of schizophrenia."

Journal • CNS Disorders • Neuroblastoma • Oncology • Psychiatry • Schizophrenia • Solid Tumor • ACTG1 • CLTC

Effects of Dopaminergic Stimulation on Reward Learning in Healthy and Depressed Individuals: A Double-Blind, Randomized Controlled fMRI Study (WFSBP 2025) - "Exploring the neural underpinnings of reward learning through the enhancement of dopaminergic signaling by amisulpride - a neuroleptic that increases dopaminergic signaling at low doses - could provide valuable insights into the etiology of MDD and potentially pave the way for improved treatments... Consistent with previous research, instrumental reward learning signals in the dorsal striatum are markedly diminished in the depressed brain, highlighting a potential biomarker for impaired learning from rewarding experiences in depression. Notably, pharmacological stimulation of dopaminergic pathways enhances neural reward learning signals in regions associated with salience and reward processing, underscoring that reward learning is critically dependent on dopaminergic signaling. Contrary to expectations, however, this effect pertained to healthy subjects only."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry